Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia
Atherosclerosis, Volume 171, No. 2, Year 2003
Notification
URL copied to clipboard!
Description
This study assessed the efficacy and safety of avasimibe (CI-1011), an inhibitor of acyl coenzyme A-cholesterol acyltransferase (ACAT) in subjects with homozygous familial hypercholesterolemia (HoFH). Twenty seven subjects were enrolled in a double-blind, randomized, 3-sequence crossover trial of atorvastatin 80mg QD, avasimibe 750mg QD, and the combined treatment of atorvastatin 80mg QD and avasimibe 750mg QD after a washout period of 4 weeks. Each treatment period was administered over 6 weeks for a total of 18 weeks. There were no significant lipid changes resulting from the administration of avasimibe monotherapy. Avasimibe in combination with atorvastatin resulted in a significantly better reduction of total cholesterol (TC) as compared to atorvastatin alone (-22% versus -18%) (P<0.05). All other lipid changes were not statistically significant for combination therapy compared to atorvastatin monotherapy, however there were greater reductions in triglycerides (TG) (-24% versus -13%), low-density lipoprotein cholesterol (LDL-C) (-23% versus -19%), very low-density lipoprotein cholesterol (VLDL-C) (-24% versus -13%) and high-density lipoprotein cholesterol (HDL-C) (-11% versus -6%). Avasimibe may modestly enhance the lipid-reducing effect of atorvastatin by further inhibiting the production of intracellular cholesterol through mechanisms that appear to be compatible in this population. © 2003 Elsevier Ireland Ltd. All rights reserved.
Authors & Co-Authors
Raal, Frederick Johan
South Africa, Johannesburg
Charlotte Maxeke Johannesburg Academic Hospital
Marais, Adrian David
South Africa, Cape Town
Faculty of Health Sciences
Klepack, Ellen
United States, New York
Pfizer Inc.
Lovalvo, Jennifer
United States, New York
Pfizer Inc.
McLain, Richard
United States, New York
Pfizer Inc.
Heinonen, Therese
United States, New York
Pfizer Inc.
Statistics
Citations: 6
Authors: 6
Affiliations: 3
Identifiers
Doi:
10.1016/j.atherosclerosis.2003.07.011
Research Areas
Disability
Study Design
Cross Sectional Study